{
  "id": 16090,
  "label": "acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent",
  "model": {
    "label": "Mondo Disease Ontology (MONDO)",
    "source": 0
  },
  "type_id": 0,
  "reference_id": "MONDO:0015164",
  "properties": {
    "xrefs": [
      "GARD:0019835",
      "MEDGEN:233970",
      "NCIT:C27913",
      "Orphanet:102379",
      "UMLS:C1332234",
      "icd11.foundation:1401970160"
    ],
    "synonyms": [
      "AML and myelodysplastic syndromes related to alkylating agent"
    ],
    "categories": [
      {
        "ref": "MONDO:0002081",
        "name": "musculoskeletal system disorder"
      },
      {
        "ref": "MONDO:0003900",
        "name": "connective tissue disorder"
      },
      {
        "ref": "MONDO:0005046",
        "name": "immune system disorder"
      },
      {
        "ref": "MONDO:0005570",
        "name": "hematologic disorder"
      }
    ],
    "definition": "Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent is a subgroup of therapy-related myeloid neoplasms (t-MN), associated with a treatment of an unrelated neoplastic or autoimmune disease with cytotoxic agents, like cyclophosphamid, platins, melphalan and others. The neoplastic cells typically harbor unbalanced aberrations of chromosomes 5 and 7 (monosomy 5/del(5q) and monosomy 7/del(7q)) or a complex karyotype. It usually presents with multilineage dysplasia and cytopenias 5-10 years after exposure, with symptoms related to the degree of bone marrow failure and the corresponding cytopenia (fatigue, bleeding and bruising, recurrent infections, bone pain)."
  },
  "isLeaf": true,
  "isRoot": false,
  "child_count": 0,
  "parents": [
    {
      "id": 19283,
      "label": "therapy related acute myeloid leukemia and myelodysplastic syndrome",
      "isLeaf": false,
      "isRoot": false,
      "parents": [
        18806
      ],
      "type_id": 0,
      "properties": {
        "xrefs": [
          "GARD:0012762",
          "MEDGEN:220954",
          "NCIT:C25765",
          "Orphanet:86846",
          "SCTID:721306009",
          "UMLS:C1292776",
          "icd11.foundation:1581599493"
        ],
        "synonyms": [
          "Secondary AGL",
          "Secondary Acute granulocytic Leukaemia",
          "Secondary Acute granulocytic Leukemia",
          "Secondary Acute myeloblastic Leukaemia",
          "Secondary Acute myeloblastic Leukemia",
          "Secondary Acute myelocytic Leukaemia",
          "Secondary Acute myelocytic Leukemia",
          "Secondary Acute myelogenous Leukaemia",
          "Secondary Acute myelogenous Leukemia",
          "Secondary Acute myeloid Leukaemia (AML)",
          "Secondary Acute myeloid Leukemia (AML)",
          "secondary AML",
          "secondary acute myeloid leukaemia",
          "secondary acute myeloid leukemia",
          "therapy-related AML and myelodysplastic syndrome"
        ],
        "categories": [
          {
            "ref": "MONDO:0002081",
            "name": "musculoskeletal system disorder"
          },
          {
            "ref": "MONDO:0003900",
            "name": "connective tissue disorder"
          },
          {
            "ref": "MONDO:0005046",
            "name": "immune system disorder"
          },
          {
            "ref": "MONDO:0005570",
            "name": "hematologic disorder"
          }
        ],
        "definition": "An acute myeloid leukemia secondary to a myelodysplastic syndrome or therapy-related. (WHO, 2001)"
      },
      "child_count": 3,
      "reference_id": "MONDO:0019457"
    }
  ],
  "children": [],
  "roots": [
    {
      "id": 19283,
      "label": "therapy related acute myeloid leukemia and myelodysplastic syndrome"
    }
  ]
}